Table 1. Demography, clinical features and tumour responses of patients treated with cetuximab and bevacizumab regimensa.
| |
Total no. of patients
(%), (n=170)b |
|
|
|---|---|---|---|
| Demographic and clinical features | Cetuximab regimens (n=124) | Bevacizumab regimens (n=100) | P-valuec |
| Gender, male/female |
78/46 (62.9/37.1) |
50/50 (50/50) |
0.058 |
| Age, mean (ranges) |
52 (25–75) |
52 (30–74) |
0.804 |
| ECOG performance status, 0/1/2 |
19/101/4 (15.3/81.5/3.2) |
13/86/1 (13/86/1) |
0.455 |
| Primary tumour site, colon/rectum |
75/49 (60.5/39.5) |
62/38 (62/38) |
0.891 |
| Curative tumour resection |
57 (46) |
49 (49) |
0.678 |
| No. of prior chemotherapy lines, 0/1/2/⩾3 |
16/19/53/36 (12.9/15.3/42.7/29) |
22/35/24/19 (22/35/24/19) |
<0.001 |
| No. of metastatic sites, 1/2/⩾3 |
33/34/57 (26.6/27.4/46) |
20/33/47 (20/33/47) |
0.447 |
| Tumour responsesd |
|
|
0.74 |
| CR | 3 (2.4) | 4 (4) | |
| PR | 40 (32.3) | 28 (28) | |
| SD | 46 (37.1) | 35 (35) | |
| PD |
35 (28.2) |
33 (33) |
|
|
Survival period, mean±s.e.m, months | |||
| PFS (ranges) | 6.2±0.4 (0.8–25) | 6.9±0.4 (1.1–14.3) | 0.123 |
| OS (ranges) | 10.2±0.6 (1–25) | 10.7±0.9 (0.8–37.8) | 0.86 |
Abbreviations: CR=complete response; ECOG=Eastern Cooperative Oncology Group; 5-FU=5-fluorouracil; OS=overall survival; PFS=progression-free survival; PD=progressive disease; PR=partial response; SD=stable disease.
Bold font, P<0.05.
a
Either irinotecan or oxaliplatin was combined to cetuximab and bevacizumab with 5-FU/leucovorin (FL) or capecitabine, namely, FOLFIRI and XELIRI or FOLFOX and XELOX.
b
Including 54 patients receiving crossover treatments.
c
Comparison between cetuximab and bevacizumab regimens by Pearson's χ2-test or unpaired t-test.
d
Assessment using RECIST criteria (Therasse et al, 2000).